Mobia Medical (NASDAQ:MOBI) Director Purchases $409,433.72 in Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 35,572 shares of Mobia Medical stock in a transaction that occurred on Thursday, August 13th. The stock was bought at an average price of $11.51 per share, with a total value of $409,433.72. Following the purchase, the director directly owned 268,904 shares of the company’s stock, valued at approximately $3,095,085.04. This trade represents a 15.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Mobia Medical Price Performance

Shares of NASDAQ:MOBI opened at $10.95 on Friday. The stock’s 50 day moving average price is $12.35. The stock has a market cap of $364.54 million and a price-to-earnings ratio of -0.54. Mobia Medical, Inc. has a 12 month low of $10.19 and a 12 month high of $15.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Mobia Medical (NASDAQ:MOBI) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. Mobia Medical’s revenue for the quarter was up 102.4% compared to the same quarter last year. On average, equities analysts anticipate that Mobia Medical, Inc. will post -2.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on MOBI shares. Wall Street Zen upgraded shares of Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. JPMorgan Chase & Co. boosted their price target on Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Bank of America initiated coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $19.00 target price on shares of Mobia Medical in a research report on Wednesday, August 12th. Finally, Wolfe Research initiated coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They set an “outperform” rating for the company. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.75.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.